Top Markets
Coin of the day
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
株式のランク #29696
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
株価
$0.00846342
時価総額
$20.02M
変化(1日)
0.00%
変化(1年)
-47.56%
AU
取引 Radiopharm Theranostics Limited (RAD)

カテゴリー

Radiopharm Theranostics Limited(RAD)のP/S比率
2026 時点のP/S比率 TTM: 0
Radiopharm Theranostics Limited の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
Radiopharm Theranostics Limited の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率